Japanese Journal of Cancer and Chemotherapy最新文献_第6页

[Bladder Preservation Therapy for Bladder Cancer]. [膀胱癌的膀胱保存治疗]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Hajime Tanaka, Yasuhisa Fujii

{"title":"[Bladder Preservation Therapy for Bladder Cancer].","authors":"Hajime Tanaka, Yasuhisa Fujii","doi":"","DOIUrl":"","url":null,"abstract":"Bladder cancer is classified into non-muscle-invasive bladder cancer(NMIBC)and muscle-invasive bladder cancer(MIBC).The prognosis for patients with NMIBC is generally favorable, and initial treatment for NMIBC typically involves transurethral resection of bladder tumor(TURBT), along with bladder instillation therapy based on risk stratification, with the goal of controlling the cancer while preserving the bladder. For cases at high risk of recurrence or progression, Bacillus Calmette-Guérin(BCG)intravesical therapy is used to prevent these events and ultimately avoid radical cystectomy. However, some patients exhibit BCG-unresponsive disease, defined as high-grade cancer persisting or recurring early after adequate BCG treatment. For BCG-unresponsive NMIBC, radical cystectomy is typically considered. However, recent advances are focused on the development of novel treatments aimed at bladder preservation in this patient population, offering hope for further progress in the future. The standard treatment for MIBC is radical cystectomy, but there is a certain number of patients who are either unfit for or unwilling to undergo this procedure. Addressing treatment options for these patients remains a significant unmet need. Recently, bladder preservation therapies using a multimodal approach, including trimodality therapy, have emerged as potential treatment options for MIBC. Appropriate patient selection, as well as further refinement and standardization of treatment protocols, remain key challenges.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"217-223"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Laparoscopic Proximal Sigmoid Colon Cancer Surgery Using Surgical-Assisted CT Colonography]. [利用手术辅助 CT 结肠造影进行腹腔镜乙状结肠近端癌手术]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Kazuo Narushima, Toru Tonooka, Hiroaki Soda, Hiroyuki Amagai, Satoshi Chiba, Hiroshi Suito, Tetsuro Isozaki, Naoki Kuwayama, Kiyohiko Shuto, Mikito Mori, Masayuki Kano, Yoshihiro Nabeya

{"title":"[Laparoscopic Proximal Sigmoid Colon Cancer Surgery Using Surgical-Assisted CT Colonography].","authors":"Kazuo Narushima, Toru Tonooka, Hiroaki Soda, Hiroyuki Amagai, Satoshi Chiba, Hiroshi Suito, Tetsuro Isozaki, Naoki Kuwayama, Kiyohiko Shuto, Mikito Mori, Masayuki Kano, Yoshihiro Nabeya","doi":"","DOIUrl":"","url":null,"abstract":"Background and purpose: Preoperative understanding of the vascular morphology is important for preservation of the distal sigmoid colon and intraluminal processing of the mesentery in laparoscopic proximal sigmoid colon cancer surgery. We report a case of laparoscopic proximal sigmoid colon cancer surgery using sophisticated surgical-assisted CT colonography (CTC). The surgical-assisted CTC was created by combining a CTC created using SYNAPSE VINCENT and a vascular 3D-CT.Patient and method: The patient was a woman in 80s with proximal sigmoid colon cancer, cT1bN0M0, cStage Ⅰ. The patient had a history of ascending colon cancer surgery. Contrast-enhanced CTC was performed preoperatively, and 3D-CT images(CTC, arterial 3D-CT, and venous 3D-CT)were created by Workstation(SYNAPSE VINCENT®, FUJIFILM).Result: Using surgical-assisted CTC, D3 lymph node dissection, in which only the dominant artery, the first and second sigmoid colon artery, and its companion veins were processed, and enterotomy and mesenterotomy line at 10 cm on the oral and anal sides were simulated. Intraoperatively, surgery was performed as planned using surgical-assisted CTC as navigation images. The operative time was 197 minutes, and the blood loss was 30 g. The patient was discharged from the hospital on the 8th day without any postoperative complications. The pathological diagnosis was pT1bN0M0, pStage Ⅰ. There was no recurrence about 9 months after the surgery.Conclusion: The sophisticated surgical-assisted CTC appeared to be useful in laparoscopic proximal sigmoid colon cancer surgery.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"249-251"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pancreaticopleural Fistula in a Patient with Metastatic Gastric Cancer]. [一名转移性胃癌患者的胰腺胸膜瘘】。］

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Daiki Matsubara, Shuhei Komatsu, Tomoki Konishi, Shun Ito, Ryo Takeda, Soichiro Ogawa, Yoshihisa Matsumoto, Yuji Fujita, Hisataka Matsuo, Yoshiaki Kuriu, Hisashi Ikoma, Katsumi Shimomura, Kazuma Okamoto, Eigo Otsuji

引用次数: 0

[A Case of Myocardial Dysfunction in a Patient with Recurrent Colon Cancer Treated with Bevacizumab]. [贝伐单抗治疗复发性结肠癌患者的心肌功能障碍病例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Takao Tamesa, Hiroki Umeno, Masahito Kinoshita, Kou Kanesada, Junya Kondo, Yoriomi Hamada, Toshikazu Gondo

{"title":"[A Case of Myocardial Dysfunction in a Patient with Recurrent Colon Cancer Treated with Bevacizumab].","authors":"Takao Tamesa, Hiroki Umeno, Masahito Kinoshita, Kou Kanesada, Junya Kondo, Yoriomi Hamada, Toshikazu Gondo","doi":"","DOIUrl":"","url":null,"abstract":"An 86-year-old man underwent laparoscopic ileocecal resection with lymph node dissection(pT3N0M0, Stage Ⅱa, Ly1a, V1a). The patient did not receive any adjuvant chemotherapy. Two years later, the patient was diagnosed with a recurrence at the anastomotic site(RAS mutant, HER2 negative, MSI-low). After 4 courses of FOLFOX plus bevacizumab, the patient was admitted for ileus. Preoperative echocardiography revealed an ejection fraction(EF)of 35% and BNP level of 562.2 pg/ mL. Therefore, asymptomatic cardiomyopathy was suspected because of bevacizumab administration. Although the last bevacizumab dose was administered within 2 weeks, we performed a laparoscopic tumor resection with lymph node dissection. Histological examination revealed colon cancer recurrence without lymph node metastasis. The patient was discharged on 19 POD without heart failure and had no recurrence of UFT/UZEL for 11 months. Three months after surgery, EF increased to 61% and BNP level was 14 pg/mL. VEGF inhibitors are associated with a very high risk of cardiomyopathy according to the ESC guidelines(2022). These side effects in conversion therapy for cancer should be carefully considered, even though they are rare.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"266-268"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Prospective Clinical Study on the Continuation Rate of Recording Electronic Patient-Reported Outcomes and Electronic Medication Notebook by Patients and the Rate of Information Reference by Attending Physicians in Cancer Chemotherapy]. [肿瘤化疗患者电子报告结局和电子用药笔记记录延续率及主治医师信息引用率的前瞻性临床研究]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Michiyo Kawai, Mamoru Hiroe, Yoshiharu Miyata, Yoichi Kurebayashi

{"title":"[A Prospective Clinical Study on the Continuation Rate of Recording Electronic Patient-Reported Outcomes and Electronic Medication Notebook by Patients and the Rate of Information Reference by Attending Physicians in Cancer Chemotherapy].","authors":"Michiyo Kawai, Mamoru Hiroe, Yoshiharu Miyata, Yoichi Kurebayashi","doi":"","DOIUrl":"","url":null,"abstract":"This prospective observational clinical study examined the adherence of patients with cancer undergoing outpatient chemotherapy to recording Electronic Patient-Reported Outcomes(ePRO)and using electronic medication notebooks, as well as the rate of information reference by attending physicians during outpatient consultations. Among 20 patients enrolled across 3 hospitals, including Kobe University Hospital, 18 consistently maintained ePRO and electronic medication notebook entries throughout the 180-day observation period. Post-observation interviews revealed that all attending physicians referred to a summary viewer integrating ePRO and electronic medication notebook data during outpatient consultations. The integration provided physicians with a more accurate understanding of patients' daily lives in a short time. These findings provide further evidence for the usefulness of ePRO and electronic medication notebooks for monitoring the health conditions of patients with cancer outside the hospital settings.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"225-229"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Active Surveillance and Focal Therapy in Localized Prostate Cancer from the Perspective of Organ Preservation Strategy]. [从器官保存策略看局部前列腺癌的主动监测和局灶治疗]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Yoichiro Tohi, Mikio Sugimoto

{"title":"[Active Surveillance and Focal Therapy in Localized Prostate Cancer from the Perspective of Organ Preservation Strategy].","authors":"Yoichiro Tohi, Mikio Sugimoto","doi":"","DOIUrl":"","url":null,"abstract":"While the widespread use of PSA testing has led to early detection of prostate cancer, the increased diagnosis of clinically insignificant cancers has led to overtreatment, such as prostatectomy and radiation therapy. The side effects of this overtreatment may lead to a decline in the quality of life of patients. Therefore, organ- preservation strategies for localized prostate cancer are expected to combine cancer control with functional preservation and maintenance of quality of life. In this regard, active surveillance and focal therapy are ideal concepts in organ preservation. Active surveillance is an established strategy for low-risk and some intermediate-risk prostate cancers, and focal therapy is not yet recommended as primary therapy for localized prostate cancer in various guidelines. However, focal therapy as a primary treatment targets clinically significant cancer for intervention, while active surveillance is applied to manage other insignificant cancers, potentially highlighting a compatibility between the 2 approaches. We proposed a treatment strategy in which focal therapy is performed on localized lesions and then active surveillance is continued again when disease progression is observed during active surveillance. We believe that this approach is an effective way to avoid overtreatment and to maintain the patient's quality of life for a long time. Although uniformity in diagnostic imaging quality and establishment of treatment indication criteria are needed to realize this approach, it may become a new approach to prostate cancer treatment in the future.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"198-204"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case Report-Remarkable Response of mFOLFIRINOX in Recurrent Hepatic Metastasis of Intraductal Papillary Mucinous Carcinoma(IPMC)]. [mFOLFIRINOX对导管内乳头状黏液癌（IPMC）复发性肝转移的显著反应病例报告]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Yuichi Obata, Yoshinari Maeda, Himawari Kihara, Taiki Kijima, Yoshinori Kitamura, Seiichiro Ando, Tatsuhito Yamamoto

{"title":"[A Case Report-Remarkable Response of mFOLFIRINOX in Recurrent Hepatic Metastasis of Intraductal Papillary Mucinous Carcinoma(IPMC)].","authors":"Yuichi Obata, Yoshinari Maeda, Himawari Kihara, Taiki Kijima, Yoshinori Kitamura, Seiichiro Ando, Tatsuhito Yamamoto","doi":"","DOIUrl":"","url":null,"abstract":"A 76-year-old female presented with multiple pancreatic cystic lesions, the largest measuring 10 mm in diameter, which were identified during an examination by another department at our hospital. Following referral to our department, she underwent observation because CT scans showed that the lesions tended to enlarge. Subsequent MRCP confirmed a diagnosis of a mixed-type IPMN, prompting surgical intervention. A distal pancreatectomy with D2 lymphadenectomy was performed. Pathological examination revealed IPMC(pT1cpN0M0, pStage ⅠA). Postoperatively, the patient received adjuvant S-1 therapy. In the second year after surgery, CT and MRI revealed hepatic recurrence in segments S8(12 mm)and S5 (5 mm). mFOLFIRINOX was initiated, and after 8 courses, a follow-up CT showed the complete disappearance of both lesions, achieving a complete response(CR). mFOLFIRINOX was continued for 21 courses, without recurrence, over the subsequent year. This case highlights the efficacy of mFOLFIRINOX in treating recurrent hepatic metastases of IPMC and warrants further investigation.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"263-265"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Laparoscopic Splenectomy after Distal Gastrectomy for Gastric Cancer]. [胃癌远端胃切除术后腹腔镜脾切除术一例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Junji Kawada, Minami Maruyama, Yoshitaka Okauchi, Tomonori Nomura, Yuji Ikeda, Manatsu Mizuno, Satoshi Eguchi, Yoshiki Taniguchi, Hiromitsu Hoshino, Shinya Yamashita, Hitoshi Mizuno, Yo Sasaki

{"title":"[A Case of Laparoscopic Splenectomy after Distal Gastrectomy for Gastric Cancer].","authors":"Junji Kawada, Minami Maruyama, Yoshitaka Okauchi, Tomonori Nomura, Yuji Ikeda, Manatsu Mizuno, Satoshi Eguchi, Yoshiki Taniguchi, Hiromitsu Hoshino, Shinya Yamashita, Hitoshi Mizuno, Yo Sasaki","doi":"","DOIUrl":"","url":null,"abstract":"We report a case of laparoscopic splenectomy after distal gastrectomy for gastric cancer. A 68-year-old woman underwent laparoscopic distal gastrectomy, D1+lymph node dissection and Billroth Ⅰ reconstruction for gastric cancer 5 years previously, with a final diagnosis of gastric cancer, M, Less-Ant, 0-Ⅱa, pT1b(SM), pN1(2/52), H0, P0, M0, pStage ⅠB(HER2 IHC 3+). Three years and 6 months after gastrectomy, CT scan showed a splenic tumor, and PET scan also showed FDG accumulation. Diagnosed as splenic metastasis post-gastric cancer surgery, she underwent chemotherapy with S-1, cisplatin, and trastuzumab. After 1 year and 6 months of chemotherapy, the splenic tumor showed mild shrinkage but persisted, leading to the decision for splenectomy due to difficulties in continuing chemotherapy. After laparoscopic splenectomy, intraoperative ICG fluorescence imaging confirmed blood flow in the remaining stomach, so the remnant stomach was preserved. No ischemic complications were observed postoperatively. The final pathology revealed an inflammatory pseudotumor of the spleen, and the patient is under observation. This case highlights successful management of a splenic tumor following distal gastrectomy with preservation of the remnant stomach using laparoscopic splenectomy and intraoperative ICG fluorescence imaging.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"272-274"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Recurrent Tracheal Adenoid Cystic Carcinoma Treated with Multidisciplinary Therapy]. [多学科疗法治疗复发性气管腺样囊性癌一例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Yasuki Hachisuka, Masashi Uomoto

引用次数: 0

[The Role of Kidney-Sparing Surgery for Patients with Upper Tract Urothelial Carcinoma]. [上尿路癌患者接受保肾手术的作用]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-03-01

Satoshi Katayama, Kasumi Yoshinaga, Tatsushi Kawada, Takuya Sadahira, Yusuke Tominaga, Takehiro Iwata, Shingo Nishimura, Kensuke Bekku, Tomoko Kobayashi, Kohei Edamura, Motoo Araki

{"title":"[The Role of Kidney-Sparing Surgery for Patients with Upper Tract Urothelial Carcinoma].","authors":"Satoshi Katayama, Kasumi Yoshinaga, Tatsushi Kawada, Takuya Sadahira, Yusuke Tominaga, Takehiro Iwata, Shingo Nishimura, Kensuke Bekku, Tomoko Kobayashi, Kohei Edamura, Motoo Araki","doi":"","DOIUrl":"","url":null,"abstract":"With the advancement of modern ureteroscopes and laser technology, kidney-sparing surgery(KSS)has an expanding role for patients with upper tract urothelial carcinoma(UTUC), although radical nephroureterectomy remains the gold standard. Patients with UTUC are generally elderly and often have major medical comorbidities. As such, KSS is recommended for patients with imperative indications, such as bilateral disease, renal insufficiency, or a solitary kidney, while maintaining renal function, resulting in the avoidance of potential long-term cardiovascular morbidity and hemodialysis. In addition, KSS is also advocated for low-risk patients(elective indication)based on the risk stratifications recommended by each guideline. The big issue of risk stratifications is their narrow indications at the cost of providing accuracy, but the current elective indications have been updated and expanded year by year. KSS includes endoscopic management through antegrade or retrograde access to the upper tract and segmental ureterectomy. Thulium: YAG laser in combination with Ho: YAG laser is recently used for KSS due to the advantages of its shallow penetration depth in tissue, with a reduced risk of upper urinary tract perforation. The concern regarding KSS is a high recurrence rate. Adjuvant intracavitary instillation to the upper tract has the potential to reduce the risk of recurrence. The phase Ⅲ trial assessing a mitomycin-containing reverse thermal gel (JelmytoTM)revealed the promising result despite their use not being approved in Japan. Therefore, KSS is assumed to have an increasing demand for patients with UTUC in our aged society and is expected to be widely utilized nationwide.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"210-216"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0